Ocular Therapeutix Inc
2.91 - 13.59
Join Discuss about OCUL with like-minded investors
took an OCUL dec 15c at 5.1
86 Replies 14 👍 6 🔥
my ocul ones going worthless
117 Replies 14 👍 13 🔥
those ocul calls I sold look like they will expire otm
110 Replies 15 👍 8 🔥
another technical trader likes OCUL
136 Replies 10 👍 14 🔥
like that ocul benlax I did some dd
82 Replies 7 👍 12 🔥
OCUL and POSH have ER wednesday amc
85 Replies 6 👍 13 🔥
was long $LB late last year but sold just before it ripped in the high 30s > @viking said: holding $NEE, $RTP, $EGAN, $CRSR, $PFE, $INTC, $OCUL, $MCD, $MDLZ long. mostly swings except for the staples are just long term positions. Short $GME, $ZOM, $IWM all swings. Will be looking to add more short swings next week. Doing some DD on $LB this weekend.
88 Replies 7 👍 6 🔥
holding $NEE, $RTP, $EGAN, $CRSR, $PFE, $INTC, $OCUL, $MCD, $MDLZ long. mostly swings except for the staples are just long term positions. Short $GME, $ZOM, $IWM all swings. Will be looking to add more short swings next week. Doing some DD on $LB this weekend.
131 Replies 8 👍 9 🔥
Next Dividend Date
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
CEO: Antony Mattessich
HQ: 24 Crosby Dr Bedford, 01730-1402 Massachusetts